VIPR2 Antikörper (AA 334-393)
Kurzübersicht für VIPR2 Antikörper (AA 334-393) (ABIN1886376)
Target
Alle VIPR2 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 334-393
-
Aufreinigung
- Purified by antigen-affinity chromatography.
-
Immunogen
- Synthetic peptide contain a sequence corresponding to a region within amino acids 334 and 393 of Human VIPR2
-
-
-
-
Applikationshinweise
-
Suggested dilutions:
Western blotting: 1.500-1.3000 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- 0.1 M Tris-buffered saline with 10 % Glycerol (pH 7.0).0.01 % Thimerosal was added as a preservative.
-
Konservierungsmittel
- Thimerosal (Merthiolate)
-
Vorsichtsmaßnahmen
- Biohazard Informations: This product contains thimerosal which is hazardous.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store at -20 °C for long term preservation (recommended). Store at 4 °C for short term use.
-
-
- VIPR2 (Vasoactive Intestinal Peptide Receptor 2 (VIPR2))
-
Andere Bezeichnung
- VPAC2
-
Hintergrund
-
Vasoactive intestinal peptide (VIP, MIM 192320) and pituitary adenylate cyclase activating polypeptide (PACAP, MIM 102980) are homologous peptides that function as neurotransmitters and neuroendocrine hormones.While the receptors for VIP and PACAP share homology, they differ in their substrate specificities and expression patterns.See VIPR1 (MIM 192321) and ADCYAP1R1(MIM 102981).[supplied by OMIM]
-
Molekulargewicht
- 49 kDa
-
Gen-ID
- 7434
-
NCBI Accession
- NP_003373, NM_003382
-
Pathways
- cAMP Metabolic Process
Target
-